Sign in

    Alexandra Ramsey

    Research Analyst at William Blair & Company, L.L.C.

    Alexandra Ramsey, Ph.D., is an Equity Research Associate at William Blair & Company, specializing in the biotechnology and radiopharmaceutical sectors. She actively covers companies involved in the development and manufacturing of novel cancer treatments, including leading firms innovating in radiopharmaceuticals such as Orano Med, ITM Isotope Technologies Munich, and Nucleus RadioPharma. Ramsey began her tenure at William Blair after completing advanced academic training, contributing industry commentary as recently as 2024 on investment trends and manufacturing advancements in oncology. She holds a doctorate and applies her scientific expertise to in-depth equity research analysis, supporting senior analysts and institutional clients with data-driven market insights.

    Alexandra Ramsey's questions to NEKTAR THERAPEUTICS (NKTR) leadership

    Alexandra Ramsey's questions to NEKTAR THERAPEUTICS (NKTR) leadership • Q2 2025

    Question

    Alexandra Ramsey of William Blair asked what specific data points from the upcoming maintenance data could suggest a remittive effect for Respag, and whether a certain efficacy threshold, like EASI 90, is necessary to achieve it.

    Answer

    Chief Research & Development Officer Jonathan Zalevsky clarified that the next data readout will still be on-treatment data but will provide insights into durability with low-frequency dosing (Q12 week). Key metrics will be the deepening of responses (e.g., EASI 50 improving to EASI 75) and the maintenance of response. Regarding a remission threshold, he referenced Phase 1 data where a strong IGA response correlated with durability off-drug, but noted more data is required to confirm if a deeper response like EASI 90 leads to better remission.

    Ask Fintool Equity Research AI

    Alexandra Ramsey's questions to Viking Therapeutics (VKTX) leadership

    Alexandra Ramsey's questions to Viking Therapeutics (VKTX) leadership • Q3 2024

    Question

    Alexandra Ramsey asked about the company's philosophical approach to dosing VK2735 in a weight maintenance setting versus an active weight-loss phase. She also inquired about Viking's perspective on the optimal agonism ratio between amylin and calcitonin for its new dual agonist program.

    Answer

    Brian Lian, an executive, explained that the monthly dosing regimen is primarily envisioned for weight maintenance, offering convenience after a target weight is achieved. On the amylin program, he noted that while the ideal ratio is not fully understood, their research suggests a more balanced agonism on both amylin and calcitonin receptors appears to provide a better overall weight loss profile.

    Ask Fintool Equity Research AI